Single cEll pRofiling PErsistaNce To ImmuNothErapy
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2
NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
- Status
- RECRUITING
- Phase
- N/A
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
- Status
- RECRUITING
- Phase
- NA
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
- Status
- RECRUITING
- Phase
- PHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
- Status
- RECRUITING
- Phase
- PHASE1
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Status
- RECRUITING
- Phase
- PHASE3
Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
- Status
- RECRUITING
- Phase
- PHASE2